ArticlePostepy dermatologii i alergologii2025
Psychosocial burden of patients with mycosis fungoides and Sézary syndrome compared to other dermatological patients. Pilot study.
Article in Postepy dermatologii i alergologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cutaneous T-cell lymphoma (CTCL), including mycosis fungoides (MF) and Sézary syndrome (SS), significantly affects patients' quality of life (QoL) due to its chronic and progressive nature. Both conditions often lead to diagnostic delays and have a profound impact on daily activities and emotional well-being. Aim: This study aimed to evaluate the QoL impairment in patients with MF and SS compared to individuals with psoriasis vulgaris and other dermatological diseases. Additionally, the study explored the potential role of high-frequency ultrasound (HFUS) in monitoring CTCL. Material and methods: A total of 104 patients, including 16 with MF, 1 with SS, 34 with psoriasis, and 53 with other dermatological diseases, were recruited from the University Centre of General Dermatology and Oncodermatology of the Wroclaw Medical University. QoL was assessed using the Polish version of the Dermatology Life Quality Index (DLQI) questionnaire. Statistical analyses included descriptive statistics, the Shapiro-Wilk test, and the Kruskal-Wallis H test. Results: Patients with CTCL had reduced QoL, with DLQI scores ranging from 2 to 22 (median: 10). However, intergroup comparisons showed no statistically significant differences between CTCL, psoriasis, and other dermatological disorders. HFUS emerged as a promising tool for assessing disease progression by measuring epidermal thickness, subepidermal low-echogenic band (SLEB) changes. Conclusions: CTCL significantly impairs QoL, necessitating individualized management strategies. While treatments like low-dose total skin electron beam therapy (TSEBT) and extracorporeal photopheresis (ECP) offer QoL improvements, disease progression remains a concern. HFUS shows potential as a non-invasive diagnostic and monitoring tool, but further research is needed to validate its routine clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.